Anavex to present at Neuroscience 2012 in New Orleans
VANCOUVER, Oct. 12, 2012 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces that new data on ANAVEX 2-73 will be presented in a poster session at Neuroscience 2012 in New Orleans. ANAVEX 2-73 is the company's lead compound for Alzheimer's disease currently in human clinical trials. Presentation details are as follows:
|Date:||Wednesday, October 17, 2012|
|Time:||3 p.m. to 4 p.m.|
|Title:||Mitochondrial protection is induced by the novel tetrahydrofuran derivative ANAVEX2-73 after ICV injection of oligomeric Aß25-35 peptide in mice, a nontransgenic Alzheimer's disease model|
The abstract for this poster must remain confidential and cannot be disclosed until the formal presentation has been made. Pursuant to Society for Neuroscience policy, the poster and associated data may be published following its presentation at Neuroscience 2012. Anavex will publish the poster on its web site (anavex.com).
Any parties interested in meeting with the Anavex team at Neuroscience 2012 may contact the company's communications team at +1 (416) 489-0092 or firstname.lastname@example.org.
Neuroscience 2012 takes place Saturday, October 13 to Wednesday, October 17, 2012 at the Ernest N. Morial Convention Center in New Orleans. It is the premier venue for neuroscientists from around the world to debut cutting-edge research on the brain and nervous system. Additional information is available at http://www.sfn.org/am2012/home.aspx.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates. Lead compound ANAVEX 2-73, developed to treat Alzheimer's through disease modification, is in human clinical trials. A Phase 1 single ascending dose study of ANAVEX 2-73 was successfully completed in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties, and that it is well tolerated in doses up to 55mg. The company is preparing to embark on a multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to finance development or satisfy the rigorous regulatory requirements for new drugs, our ability to attract and retain quality personnel, and that despite positive results, our competitors may offer better or cheaper alternatives. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
SOURCE Anavex Life Sciences Corp.